LINCOCIN AQUADROPS- lincomycin hydrochloride liquid

देश: संयुक्त राज्य

भाषा: अंग्रेज़ी

स्रोत: NLM (National Library of Medicine)

सक्रिय संघटक:

LINCOMYCIN HYDROCHLORIDE (UNII: M6T05Z2B68) (LINCOMYCIN - UNII:BOD072YW0F)

थमां उपलब्ध:

Zoetis Inc.

प्रशासन का मार्ग:

ORAL

प्रिस्क्रिप्शन प्रकार:

PRESCRIPTION

चिकित्सीय संकेत:

LINCOCIN products are indicated in infections caused by gram-positive organisms which are sensitive to its action, particularly streptococci and staphylococci. The drug has proven effective in eradicating causative organisms in most of the common upper respiratory tract infections, in septicemia, and in infections of the skin and adjoining tissues. Systemic therapy with LINCOCIN has been shown to be of benefit in many animals with pustular dermatitis. As with all antibiotics, in vitro sensitivity studies should be performed before LINCOCIN is utilized as sole antibiotic therapy. LINCOCIN has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and sensitive to lincomycin. The drug may be administered in combination therapy with other antimicrobial agents when indicated. No serious hypersensitivity reactions have been reported and many animals have received LINCOCIN repeatedly without developing evidence of hypersensitivity. LINCOCIN has demonstrated e

उत्पाद समीक्षा:

LINCOCIN products for veterinary use are available in the following dosage forms and strengths: AQUADROPS® Each mL containing lincomycin hydrochloride equivalent to lincomycin, 50 mg; preserved with methylparaben 0.075%, propylparaben 0.025%, and sorbic acid 0.1%. Supplied in 20 mL bottles with graduated dropper. NADA #40-587, Approved by FDA.   Sterile Solution Each mL containing lincomycin hydrochloride equivalent to lincomycin, 100 mg; also Benzyl Alcohol, 9.45 mg added as preservative. Supplied in 20 mL vials. NADA #34-025, Approved by FDA.

प्राधिकरण का दर्जा:

New Animal Drug Application

उत्पाद विशेषताएं

LINCOCIN AQUADROPS- LINCOMYCIN HYDROCHLORIDE LIQUID
ZOETIS INC.
----------
LINCOCIN® LINCOMYCIN HYDROCHLORIDE LIQUID AND LINCOMYCIN INJECTION,
USP
FOR USE IN ANIMALS ONLY
FOR INTRAMUSCULAR, INTRAVENOUS, AND ORAL USE IN DOGS AND CATS.
CAUTION: Federal (USA) law restricts this drug to use by or on the
order of a licensed veterinarian.
DESCRIPTION
LINCOCIN products contain lincomycin hydrochloride, an antibiotic
produced by _Streptomyces_
_lincolnensis var. lincolnensis_, which is chemically distinct from
all other clinically available antibiotics
and is isolated as a white crystalline solid. It is stable in the dry
state and in aqueous solution for at least
24 months. Lincomycin hydrochloride is readily soluble in water at
room temperature in concentrations
up to 500 mg/mL. Physical stability of aqueous solutions can be
maintained at drug concentrations up to
345 mg/mL at temperatures as low as 4° C. The solubility in 95
percent ethanol is 80 mg/mL.
LINCOCIN products have been shown to be effective against most of the
common gram-positive
pathogens. Depending on the sensitivity of the organism and
concentration of the antibiotic, it may be
either bactericidal or bacteriostatic. It has not shown cross
resistance with other available antibiotics.
Microorganisms have not developed resistance to LINCOCIN rapidly when
tested by _in vitro _or _in vivo_
methods.
CLINICAL PHARMACOLOGY
CLINICAL ABSORPTION AND EXCRETION
Administered intramuscularly, LINCOCIN Sterile Solution is very
rapidly absorbed. In studies with
dogs, peak serum levels were reached in from ten minutes to two hours
with detectable levels for 16 to
24 hours. The concentration of LINCOCIN in the blood serum varies with
the dose administered and
with the individual animal. Levels are maintained above the _in vitro
_minimum inhibitory concentration for
most gram-positive organisms for six to eight hours following a
therapeutic dose. Intravenous
administration also provides very rapid absorption, but should be
administered with normal saline or 5%
glucose as